Researchers are revealing the complexity of the microbial community living on the body—and paving the way for new bacteria-targeting treatments for acne and other dermatological conditions.

The biotech industry is chipping away at the obstacles standing between the lab and the dinner plate.

RNA editing has been in DNA editing’s shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.

Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.

Tired of dancing to the tunes of international funders, and doubtful that long-promised national grants will come, a handful of African biomedical scientists have turned to private investors to bankroll their dreams of autonomy in the lab.

With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

The recent move of the European Medicines Agency from London to Amsterdam is a reflection of the city’s vibrant life sciences and health sector and supporting industries.

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.

A nascent but growing consumer market for brain-computer interface technology is driving the development of sleek new tools for decoding brain activity.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

Digital biomarkers of cognitive decline could alert us to the early stages of dementia before irreversible damage occurs.

There’s a new cell-based cancer immunotherapy on the block.

The US lacks standardized methods to assess products for potency and safety. That’s a big problem for the labs tasked with doing the testing.

The midwestern state has quietly laid the groundwork for a biotech hub.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

Insulin-producing cells grown in the lab could offer a functional cure for the disease.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.